Compare ZDAI & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDAI | QNME |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Integrated Freight & Logistics |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 10.5M |
| IPO Year | 2023 | 2024 |
| Metric | ZDAI | QNME |
|---|---|---|
| Price | $1.23 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.5K | ★ 573.1K |
| Earning Date | 08-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $0.20 | $0.24 |
| 52 Week High | $11.48 | $1.40 |
| Indicator | ZDAI | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 33.15 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.61 | $0.43 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.43 | 2.36 |
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.